Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

(2014) Julio Rosenstock et al.   DIABETES CARE

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Hypoglycemia: Minimizing its Impact in Type 2 Diabetes

(2013) Etie Moghissi et al.   Endocrine Practice

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

(2013) Jan N. Basile   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

(2012) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

(2012) Anthony H. Barnett et al.   CURRENT MEDICAL RESEARCH AND OPINION

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database

(2012) Ishan Hirji et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)

(2012) Ishan Hirji et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

(2011) Giovanni Musso et al.   ANNALS OF MEDICINE

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

(2011) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

(2011) James F. List et al.   KIDNEY INTERNATIONAL

Hypoglycemia, Diabetes, and Cardiovascular Events

(2010) C. V. Desouza et al.   DIABETES CARE

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Insulin Therapy and Type 2 Diabetes: Management of Weight Gain

(2009) Samy I. McFarlane   Journal of Clinical Hypertension

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes

(2009) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Barrier of Hypoglycemia in Diabetes

(2008) P. E. Cryer   DIABETES

Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?: An argument in favor

(2008) M. C. Riddle   DIABETES CARE

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study

(2008) F. Álvarez Guisasola et al.   DIABETES OBESITY & METABOLISM

Intensification lessons with modern premixes: From clinical trial to clinical practice

(2008) Serdar Guler et al.   DIABETES RESEARCH AND CLINICAL PRACTICE